{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:05:39Z","timestamp":1785470739210,"version":"3.56.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chitinase 3-like protein 1 (CHI3L1 or YKL40) is a potential neuroinflammatory biomarker linked to the pathogenesis of Alzheimer\u2019s disease (AD). Previous studies have produced inconsistent results regarding YKL40 levels in various clinical stages of AD. This study aims to establish the correlation between YKL40 levels and AD progression through a meta-analysis of YKL40 levels in cerebrospinal fluid (CSF) and peripheral blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive searches were conducted in PubMed, Medline, Web of Science, and the Cochrane Library to identify observational studies reporting CSF and peripheral blood YKL40 levels in AD patients, mild cognitive impairment (MCI) patients, preclinical AD (pre-AD) and healthy controls (HCs). A random effects meta-analysis was used to calculate the standardized mean difference (SMD) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty observational studies involving 2,102\u202fAD patients, 1,504 MCI patients, 118 pre-AD individuals, and 2,091 HCs were included. Significant differences in CSF YKL-40 levels were observed in AD vs. HC (SMD\u202f=\u202f1.37, 95%CI: [1.09, 1.65];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.000), MCI vs. HC (SMD\u202f=\u202f0.96, 95%CI: [0.51, 1.41];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.000), and pre-AD vs. HC (SMD\u202f=\u202f0.81, 95%CI: [0.39, 1.22];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001) comparisons. Peripheral blood YKL-40 levels also demonstrated statistically significant elevations in both AD vs. HC (SMD\u202f=\u202f0.40, 95%CI: [0.18, 0.63];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.000) and MCI vs. HC (SMD\u202f=\u202f0.79, 95%CI: [0.03, 1.55];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.043) comparisons. However, CSF YKL-40 levels showed no statistically significant difference between AD and MCI groups (SMD\u202f=\u202f0.25, 95%CI: [\u22120.08, 0.57];\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.134).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Elevated YKL-40 levels in both CSF and peripheral blood are associated with the presence of Alzheimer\u2019s disease and its early stages, indicating that YKL-40 reflects neuroinflammatory processes involved in AD onset. While YKL-40 shows potential value for early identification along the AD continuum, its limited ability to differentiate between MCI and AD highlights the need for its combined use with other biomarkers in disease staging and progression assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251031837<\/jats:uri>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1768353","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:22:44Z","timestamp":1770268964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of Alzheimer\u2019s disease progression with YKL40 levels in peripheral blood and cerebrospinal fluid: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Qianwen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhui","family":"Fu","sequence":"additional","affiliation":[{"name":"International Education College, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","article-title":"Neuroinflammation in Alzheimer disease","volume":"25","author":"Heneka","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.3390\/ijms252211941","article-title":"Neuroinflammatory biomarkers in Alzheimer's disease: from pathophysiology to clinical implications","volume":"25","author":"Roveta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1111\/acel.70036","article-title":"Temporal changes in Alzheimer's disease-related biomarkers in the CSF of cognitively Normal subjects at different ages: the Chongqing ageing and dementia study","volume":"24","author":"Li","year":"2025","journal-title":"Aging Cell"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/jnnp-2022-330743","article-title":"Molecules of senescent glial cells differentiate Alzheimer's disease from ageing","volume":"94","author":"Dai","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/biomedicines9091094","article-title":"Increased YKL-40 but not C-reactive protein levels in patients with Alzheimer's disease","volume":"9","author":"Blanco-Palmero","year":"2021","journal-title":"Biomedicine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/medicina58010060","article-title":"YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer's disease","volume":"58","author":"Mavroudis","year":"2021","journal-title":"Medicina"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"112960","DOI":"10.1016\/j.exger.2025.112960","article-title":"Neurodegeneration and glial activation related blood biomarkers in Alzheimer's disease: a systematic review and an updated meta-analysis","volume":"212","author":"Ebrahimi","year":"2025","journal-title":"Exp Gerontol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3233\/JAD-191261","article-title":"Cerebrospinal fluid YKL-40 and neurogranin in familial Alzheimer's disease: a pilot study","volume":"76","author":"Thordardottir","year":"2020","journal-title":"J Alzheimer's Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e208075","DOI":"10.1212\/WNL.0000000000208075","article-title":"Association of Plasma YKL-40 with MRI, CSF, and cognitive markers of brain health and dementia","volume":"102","author":"Pase","year":"2024","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/brainsci13101364","article-title":"Peripheral blood and cerebrospinal fluid levels of YKL-40 in Alzheimer's disease: a systematic review and Meta-analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Brain Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","article-title":"Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and Meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/jnnp-2018-319148","article-title":"Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies","volume":"90","author":"Shen","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e209537","DOI":"10.1212\/WNL.0000000000209537","article-title":"Blood astrocyte biomarkers in Alzheimer disease: a systematic review and Meta-analysis","volume":"103","author":"Holper","year":"2024","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1567205018666211208142702","article-title":"Neurodegeneration and glial activation related CSF biomarker as the diagnosis of Alzheimer's disease: a systematic review and an updated meta- analysis","volume":"19","author":"Hao","year":"2022","journal-title":"Curr Alzheimer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e210225","DOI":"10.1212\/WNL.0000000000210225","article-title":"Blood-based biomarkers and risk of onset of mild cognitive impairment over the short and long term","volume":"104","author":"Soldan","year":"2025","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.3390\/ijms241713166","article-title":"The relationships between cerebrospinal fluid glial (CXCL12, CX3CL, YKL-40) and synaptic biomarkers (Ng, NPTXR) in early Alzheimer's disease","volume":"24","author":"Kulczy\u0144ska-Przybik","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"10523","DOI":"10.3390\/ijms241310523","article-title":"Central and peripheral inflammation in mild cognitive impairment in the context of Alzheimer's disease","volume":"24","author":"Schmidt-Morgenroth","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.bbih.2022.100549","article-title":"Estimation of blood-based biomarkers of glial activation related to neuroinflammation","volume":"26","author":"Yasuno","year":"2022","journal-title":"Brain Behav Immun Health."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13195-021-00899-0","article-title":"Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy","volume":"13","author":"De Kort","year":"2021","journal-title":"Alzheimer's Res Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"117353","DOI":"10.1016\/j.jns.2021.117353","article-title":"Increased plasma levels of chitinase 3-like 1 (CHI3L1) protein in patients with idiopathic normal-pressure hydrocephalus","volume":"423","author":"Ko","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/mds.28738","article-title":"Systematic assessment of 10 biomarker candidates focusing on \u03b1-Synuclein-related disorders","volume":"36","author":"Schulz","year":"2021","journal-title":"Mov Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2174\/1567205017666201109095657","article-title":"Cerebrospinal fluid and blood CX3CL1 as a potential biomarker in early diagnosis and prognosis of dementia","volume":"17","author":"Kulczy\u0144ska-Przybik","year":"2020","journal-title":"Curr Alzheimer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fneur.2020.00757","article-title":"Increased Neurofilament light chain and YKL-40 CSF levels in one Japanese IBMPFD patient with VCP R155C mutation: a clinical case report with CSF biomarker analyses","volume":"11","author":"Ikeda","year":"2020","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jalz.2019.09.001","article-title":"Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias","volume":"16","author":"Antonell","year":"2020","journal-title":"Alzheimers Dement"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JAD-200036","article-title":"Cerebrospinal fluid biomarkers to differentiate idiopathic Normal pressure hydrocephalus from subcortical ischemic vascular disease","volume":"75","author":"Manniche","year":"2020","journal-title":"J Alzheimer's Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-019-1399-2","article-title":"Glial activation and inflammation along the Alzheimer's disease continuum","volume":"16","author":"Nordengen","year":"2019","journal-title":"J Neuroinflammation"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2019.08.032","article-title":"Biomarker-guided clustering of Alzheimer's disease clinical syndromes","volume":"83","author":"Toschi","year":"2019","journal-title":"Neurobiol Aging"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","article-title":"Plasma YKL-40 in the spectrum of neurodegenerative dementia","volume":"16","author":"Villar-Piqu\u00e9","year":"2019","journal-title":"J Neuroinflammation"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jalz.2019.01.015","article-title":"Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study","volume":"15","author":"Lle\u00f3","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","article-title":"CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia","volume":"12","author":"Abu-Rumeileh","year":"2019","journal-title":"Alzheimer's Res Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1038\/s41598-019-44173-8","article-title":"Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease","volume":"9","author":"Morenas-Rodr\u00edguez","year":"2019","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jalz.2017.11.015","article-title":"Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: a\u03b2(1-42), total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40","volume":"14","author":"Hampel","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-018-0127-7","article-title":"Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl Neurodegener"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","article-title":"CSF sAPP\u03b2, YKL-40, and neurofilament light in frontotemporal lobar degeneration","volume":"89","author":"Alcolea","year":"2017","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fnagi.2017.00289","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease show different but partially overlapping profile compared to vascular dementia","volume":"9","author":"Llorens","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3233\/JAD-150746","article-title":"Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias","volume":"50","author":"Morenas-Rodr\u00edguez","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","article-title":"Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort","volume":"7","author":"Kester","year":"2015","journal-title":"Alzheimer's Res Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-140240","article-title":"Relationship between \u03b2-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"42","author":"Alcolea","year":"2014","journal-title":"J Alzheimer's Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","article-title":"Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease","volume":"42","author":"Antonell","year":"2014","journal-title":"J Alzheimer's Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2012-120787","article-title":"Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia","volume":"33","author":"Olsson","year":"2013","journal-title":"J Alzheimer's Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00415-011-6087-9","article-title":"Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease","volume":"258","author":"Choi","year":"2011","journal-title":"J Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"NeuroMolecular Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1177\/13872877251335915","article-title":"Cerebrospinal fluid inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer's disease spectrum","volume":"105","author":"Ghanbarian","year":"2025","journal-title":"J Alzheimer's Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression","volume":"20","author":"Pelkmans","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.3390\/jcm9113452","article-title":"Diagnostic utility of selected serum dementia biomarkers: amyloid \u03b2-40, amyloid \u03b2-42, tau protein, and YKL-40: a review","volume":"9","author":"Wilczy\u0144ska","year":"2020","journal-title":"J Clin Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"eadk3674","DOI":"10.1126\/sciadv.adk3674","article-title":"CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly","volume":"10","author":"Shue","year":"2024","journal-title":"Sci Adv"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"100819","DOI":"10.1016\/j.bbih.2024.100819","article-title":"\"let's talk about sex, inflammaging, and cognition, baby\": a meta-analysis and meta-regression of 106 case-control studies on mild cognitive impairment and Alzheimer's disease","volume":"40","author":"Childs","year":"2024","journal-title":"Brain Behav Immun Health"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41380-024-02753-9","article-title":"Sex\/gender effects of glial reactivity on preclinical Alzheimer's disease pathology","volume":"30","author":"Vila-Castelar","year":"2025","journal-title":"Mol Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"146305","DOI":"10.1016\/j.brainres.2019.146305","article-title":"Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease","volume":"1720","author":"Sanfilippo","year":"2019","journal-title":"Brain Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","article-title":"Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease","volume":"14","author":"Prins","year":"2022","journal-title":"Alzheimer's Res Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","article-title":"Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study","volume":"15","author":"Brosseron","year":"2023","journal-title":"Alzheimer's Res Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","article-title":"YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies","volume":"14","author":"Querol-Vilaseca","year":"2017","journal-title":"J Neuroinflammation"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12974-020-1723-x","article-title":"Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease","volume":"17","author":"Moreno-Rodriguez","year":"2020","journal-title":"J Neuroinflammation"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"eadv1492","DOI":"10.1126\/sciadv.adv1492","article-title":"CHI3L1\/YKL-40 signaling inhibits neurogenesis in models of Alzheimer's disease","volume":"11","author":"Yang","year":"2025","journal-title":"Sci Adv"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"eaax3519","DOI":"10.1126\/scitranslmed.aax3519","article-title":"Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis","volume":"12","author":"Lananna","year":"2020","journal-title":"Sci Transl Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12974-023-02970-z","article-title":"Astrocyte-specific knockout of YKL-40\/Chi3l1 reduces a\u03b2 burden and restores memory functions in 5xFAD mice","volume":"20","author":"Zeng","year":"2023","journal-title":"J Neuroinflammation"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/alz.12612","article-title":"Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer's disease","volume":"19","author":"Connolly","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/biom14010093","article-title":"Blood biomarkers of Alzheimer's disease and cognition: a literature review","volume":"14","author":"Garcia-Escobar","year":"2024","journal-title":"Biomolecules"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma biomarkers of Alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice","volume":"7","author":"Pais","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"00547","DOI":"10.1016\/j.jare.2025.07.022","article-title":"Biomarkers for Alzheimer's disease across diverse biological domains: an umbrella review and evidence map","volume":"17","author":"Kang","year":"2025","journal-title":"J Adv Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-022-01058-9","article-title":"Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease","volume":"14","author":"Giannisis","year":"2022","journal-title":"Alzheimer's Res Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","article-title":"Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer's disease","volume":"27","author":"Ferrari-Souza","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1630022","DOI":"10.3389\/fnagi.2025.1630022","article-title":"Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer's disease, with hypertensive dependency","volume":"17","author":"Wang","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","article-title":"Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum","volume":"16","author":"Mil\u00e0-Alom\u00e0","year":"2020","journal-title":"Alzheimers Dement"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e70502","DOI":"10.1002\/alz.70502","article-title":"Early microglial and astrocyte reactivity in preclinical Alzheimer's disease","volume":"21","author":"Fern\u00e1ndez-Matarrubia","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1768353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:22:45Z","timestamp":1770268965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1768353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":72,"alternative-id":["10.3389\/fneur.2026.1768353"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1768353","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1768353"}}